Trifluridine
Based on 3 publication(s) in Google Scholar
Trifluridine (Trifluorothymidine) is an irreversible and orally active thymidylate synthase inhibitor, and thereby suppressing DNA synthesis. Trifluridine is an antiviral molecule used for research of HSV, rhabdovirus and orthopoxvirus infection. Trifluridine induces cell apoptosis and autophagy. Trifluridine is also an anticancer agent used in studies of metastatic colorectal cancer, gastrointestinal tumors.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.96%
- CAS 番号: 70-00-8
- 分子式: C10H11F3N2O5
- 分子量:296.20
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
Nucleotide Compound Library
HY-L044
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Chemotherapy Drug Library
HY-L112
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Orthopoxvirus Compound Library
HY-L127
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Cancer Approved Drug Library
HY-L213
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Classic FDA-Approved Drug Library
HY-L261
-
3D Diverse Fragment Library
HY-L903
MedChemExpress（MCE）の使用を引用している文献 Trifluridine
MoreDNA/RNA Synthesis アイソフォーム固有の製品をすべて表示
More
生物活性
|
Thymidylate Synthase |
Nucleoside Antimetabolite/Analog |
HSV-1 |
HSV-2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hepatocyte | EC50 |
3.37 μM
Compound: 25
|
Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication
Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication
|
[PMID: 20857959] |
| HepG2 2.2.15 | EC50 |
10 μg/mL
Compound: 2
|
Antiviral activity against HBV infected in human 2.2.15 cell at 10 ug/ml
Antiviral activity against HBV infected in human 2.2.15 cell at 10 ug/ml
|
[PMID: 20863701] |
| Huh-7 | CC50 |
>675 μM
Compound: 25
|
Cytotoxicity against HuH7 cells
Cytotoxicity against HuH7 cells
|
[PMID: 20857959] |
| Huh-7 | CC50 |
>200 μg/mL
Compound: 2
|
Cytotoxicity against human HuH7 cells
Cytotoxicity against human HuH7 cells
|
[PMID: 20863701] |
| Vero | CC50 |
50.6 μM
Compound: TFT
|
Cytotoxicity against african green monkey Vero cells after 2 days
Cytotoxicity against african green monkey Vero cells after 2 days
|
[PMID: 17438061] |
| Vero | EC50 |
<1.7 μM
Compound: TFT
|
Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
|
[PMID: 17438061] |
| Vero | EC50 |
1.7 μM
Compound: TFT
|
Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
|
[PMID: 17438061] |
| Vero | EC50 |
3.4 μM
Compound: TFT
|
Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
|
[PMID: 17438061] |
Trifluridine (0.5 μΜ, 3 days) induces cellular senescence in HUVECs[2].
Trifluridine (0.5 μΜ, 3 days) inhibits autophagy and autophagy flux via the mTOR pathway in HUVECs [2].
Trifluridine (0-5 μΜ, 3 days) inhibits HUVEC cells viability in a concentration-dependent way[2].
Trifluridine (5 µM-20 µM, 24 h–72 h) inhibits the proliferation in MCF-7, MDA-MB-231, BT-549 and Hs578T[4].
Trifluridine (0 µM-20 µM, 48 h) selectively induces apoptosis in MCF-7, MDA-MB-231, BT-549 and Hs578T cells [4].
Trifluridine (10 µM, 72 h) induces DNA double-strand break in MCF-10A, MCF-7, MDA-MB-231 and BT-549 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HUVEC cells
-
Concentration:0-5 μM
-
Incubation Time:3 days
-
Result:Cell viability dropped sharply at 3 μM and 5 μM.
-
Cell Line:HUVEC cells
-
Concentration:0-5 μM
-
Incubation Time:3 days
-
Result:Induced cellular senescence by inhibiting autophagy flux.
-
Cell Line:HUVEC cells
-
Concentration:0-5 μM
-
Incubation Time:3 days
-
Result:Increased protein levels of senescence markers: p53, p16, SASP (IL-1, IL-6, TNF-α, p21).
-
Cell Line:MCF-7, MDA-MB-231, BT-549, Hs578T and MCF-10A(control non-tumor) cells
-
Concentration:5 µM-20 µM
-
Incubation Time:24 h–72 h
-
Result:Inhibited the proliferation of MDA-MB231, BT549 and Hs578T cells at 10µM and 20µM, significantly.
-
Cell Line:MDA-MB-231, BT-549, and Hs578T cells
-
Concentration:10µM or 20 µM
-
Incubation Time:48 h
-
Result:Increased the percentages of apoptotic TNBC cells (MDA-MB-231, BT-549, and Hs578Tcells) at 10µM and 20µM, significantly.
Trifluridine (75 or 150 mg/kg, oral gavage, once daily for 5 consecutive days) inhibits the growth in implanted mouse TNBC tumors [4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice (human colorectal intraperitoneal xenograft model)[3]
-
Dosage:200 mg/kg(trifluridine/tipiracil)
-
Administration:Oral administration; Once a day; 5 days followed by 2 drug-free days, a total of 6 weeks
-
Result:Exhibited a significantly longer survival time compared with untreated mice.
-
Animal Model:Mouse model of breast cancer[4]
-
Dosage:75 or 150 mg/kg
-
Administration:Oral gavage; daily for 10 days
-
Result:Treatment with different doses inhibited the growth of TNBC tumors in mouse in a dose-dependent manner
-
Animal Model:The human gastric MKN45 intraperitoneal xenograft model[3]
-
Dosage:200 mg/kg (Trifluridine/tipiracil)
-
Administration:twice daily for 5 consecutive days followed by 2 drug‑free days for 6 weeks
-
Result:Prolonged the survival of mice compared with untreated mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 70-00-8
-
性状 Solid
-
分子量 296.20
-
分子式 C10H11F3N2O5
-
Color White to off-white
-
SMILES
O[C@H]1C[C@H](N2C(NC(C(C(F)(F)F)=C2)=O)=O)O[C@@H]1CO
-
別名
TFT; トリフルオロチミジン; Trifluorothymidine; 5-Trifluorothymidine
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
PLoS Pathog
Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]2026 Jan 26;22(1):e1013903. PMID: 41587213 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471
溶剤 & 溶解度
DMSO : ≥ 100 mg/mL (337.61 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 33.33 mg/mL (112.53 mM; ultrasonic and warming and heat to 60°C)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
純度とドキュメンテーション
-
データシート (286 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Portuguese - PT (419 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Okayama T, et al. Involvement of concentrative nucleoside transporter 1 in intestinal absorption of trifluorothymidine, a novel antitumor nucleoside, in rats. J Pharmacol Exp Ther. 2012 Feb;340(2):457-62. [Content Brief]
[2]. Jia HJ, et al. Trifluridine induces HUVECs senescence by inhibiting mTOR-dependent autophagy. Biochem Biophys Res Commun. 2022 Jun 25;610:119-126. [Content Brief]
[3]. Suzuki N,et al. Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer. Oncol Lett. 2017 Jul;14(1):639-646. [Content Brief]
[4]. Li J, et al. Trifluridine selectively inhibits cell growth and induces cell apoptosis of triple-negative breast cancer. Am J Cancer Res. 2020 Feb 1;10(2):507-522. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.3761 mL | 16.8805 mL | 33.7610 mL | 84.4024 mL |
| 5 mM | 0.6752 mL | 3.3761 mL | 6.7522 mL | 16.8805 mL | |
| 10 mM | 0.3376 mL | 1.6880 mL | 3.3761 mL | 8.4402 mL | |
| 15 mM | 0.2251 mL | 1.1254 mL | 2.2507 mL | 5.6268 mL | |
| 20 mM | 0.1688 mL | 0.8440 mL | 1.6880 mL | 4.2201 mL | |
| 25 mM | 0.1350 mL | 0.6752 mL | 1.3504 mL | 3.3761 mL | |
| 30 mM | 0.1125 mL | 0.5627 mL | 1.1254 mL | 2.8134 mL | |
| 40 mM | 0.0844 mL | 0.4220 mL | 0.8440 mL | 2.1101 mL | |
| 50 mM | 0.0675 mL | 0.3376 mL | 0.6752 mL | 1.6880 mL | |
| 60 mM | 0.0563 mL | 0.2813 mL | 0.5627 mL | 1.4067 mL | |
| 80 mM | 0.0422 mL | 0.2110 mL | 0.4220 mL | 1.0550 mL | |
| 100 mM | 0.0338 mL | 0.1688 mL | 0.3376 mL | 0.8440 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz